Repositori Obert UdL
Publicación
Artículo científico (JournalArticle)
Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men
Background : An altered gut microbiome characterized by reduced abundance of butyrate producing bacteria and reduced gene richness is associated with type 2 diabetes (T2D). An important complication of T2D is increased risk of cognitive impairment and dementia. The biguanide metformin is a commonly prescribed medication for the control of T2D and metformin treatment has been associated with a significant reduction in the risk of dementia and improved cognition, particularly in people with T2D.
Aim : To investigate the associations of metformin use with cognition exploring potential mechanisms by analyzing the gut microbiome and plasma metabolome using shotgun metagenomics and HPLC-ESI-MS/MS, respectively.
Methods : We explored two independent cohorts: an observational study (Aging Imageomics) and a phase IV, randomized, double-blind, parallel-group, randomized pilot study (MEIFLO). From the two studies, we analyzed four study groups: (1) individuals with no documented medical history or medical treatment (n = 172); (2) people with long-term T2D on metformin monotherapy (n = 134); (3) people with long-term T2D treated with oral hypoglycemic agents other than metformin (n = 45); (4) a newly diagnosed T2D subjects on metformin monotherapy (n = 22). Analyses were also performed stratifying by sex.
Results : Several bacterial species belonging to the Proteobacteria (Escherichia coli) and Verrucomicrobia (Akkermansia muciniphila) phyla were positively associated with metformin treatment, while bacterial species belonging to the Firmicutes phylum (Romboutsia timonensis, Romboutsia ilealis) were negatively associated. Due to the consistent increase in A. muciniphila and decrease in R.ilealis in people with T2D subjects treated with metformin, we investigated the association between this ratio and cognition. In the entire cohort of metformin-treated T2D subjects, the A.muciniphila/R.ilealis ratio was not significantly associated with cognitive test scores. However, after stratifying by sex, the A.muciniphila/R. ilealis ratio was significantly and positively associated with higher memory scores and improved memory in men.
Metformin treatment was associated with an enrichment of microbial pathways involved in the TCA cycle, and butanoate, arginine, and proline metabolism in both cohorts. The bacterial genes involved in arginine metabolism, especially in production of glutamate (astA, astB, astC, astD, astE, putA), were enriched following metformin intake. In agreement, in the metabolomics analysis, metformin treatment was strongly associated with the amino acid proline, a metabolite involved in the metabolism of glutamate.
Conclusions : The beneficial effects of metformin may be mediated by changes in the composition of the gut microbiota and microbial-host-derived co-metabolites., This work was partially funded by Instituto de Salud Carlos III (ISCIII, Madrid, Spain) through the projects PI15/01934 and PI21/ 01361 to J.M.F-R and the project PI20/01090 and PI23/00575 (co-funded by the European Union under the European Regional Development Fund (FEDER) “A way to make Europe”) to J.M-P. Generalitat de Catalunya (2021 SGR 01263). M.R.D. is funded by Girona Biomedical Research Institute (Girona, Spain) through the Horizon 2020 Framework Programme of the European Union under the Marie Skłodowska- Curie Innovative Training Network grant agreement No 859890. Open Access funding provided by the CRUE-CSIC agreement with Elsevier. The Aging Imageomics Study has been funded by Pla estrat`egic de recerca i innovaci´o en salut 2016-2020 from Generalitat de Catalunya (reference number, SLT002/16/00250). IRBLleida is a CERCA Programme of the Government of Catalonia. IDIBGI is a CERCA Programme/Generalitat de Catalunya. M.J. is a ‘Serra-Hunter’ Fellow. J.M.- P. is funded by Instituto de Salud Carlos III (Madrid, Spain) through the Miguel Servet Program CP18/00009 (co-funded by European Union under the European Social Fund “Investing in your future”). J.M.-P. was also supported through the project CNS2023-144218 funded by MICIU/ AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR.